Published in Hepatitis Weekly, May 5th, 2008
Studies 102 and 103 were designed to evaluate treatment with Viread over 240 weeks among patients with HBeAg-negative (presumed pre-core mutant) and HBeAg-positive chronic...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Hepatitis Weekly